08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Afferent, Roche deal

Newco Afferent received exclusive, worldwide rights to develop and commercialize Roche 's P2X3 receptor program, including lead compound AF-219 (formerly RG1646 /RO 4926219). The P2X3 antagonist is expected to start Phase II testing for pain...